After rejecting it three times, FDA has now approved AVEED, a new testosterone and castor oil therapy manufactured by Endo International to treat male hypogonadism. Male hypogonadism is characterized by low production of testosterone which is responsible for maintaining muscle bulk, bone growth and sexual function. The FDA had been concerned about the risk of the castor oil causing blockages in blood vessels in the lungs and complications linked to post-injection reactions. However, FDA determined that the benefits of testosterone therapy outweighed these risks. Following the approval, AVEED is expected to be available later in March.
[1] Reuters, "FDA approves Endo International's testosterone drug" (March 6, 2014).
[2] FDA Approved Drug Products, AVEED (March 5, 2014).
[1] Reuters, "FDA approves Endo International's testosterone drug" (March 6, 2014).
[2] FDA Approved Drug Products, AVEED (March 5, 2014).
RSS Feed
